Should I buy Bristol Myers Squibb (BMY) stock or is it too late?

Bristol Myers Squibb · Health Care · price $67

See the full Bristol Myers Squibb (BMY) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: B of A Securities — 68% of its targets hit on this sector (356 calls tested). It aims for $66 (-1.4 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).

The 7 reliable analysts $70+4.6 %

The 3 other firms $60-10 %

How to read it: the 7 reliable firms are not filtered by optimism — 5 aim above the price, 2 below, hence their $70 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Bristol Myers Squibb

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Goldman Sachs	100 %	+29.4 %	5	$57 -15%
Jefferies	73 %	+18.8 %	11	$68 +2%
Barclays	100 %	+11.2 %	5	$75 +12%
BMO Capital	67 %	+10.3 %	15	$61 -9%
Morgan Stanley	81 %	+10.0 %	16	$37 -45%
B of A Securities	60 %	+1.5 %	5	$66 -1%
JP Morgan	40 %	-0.1 %	5	$73 +9%
Citigroup	40 %	-3.2 %	5	$70 +5%

In short — Should you invest in Bristol Myers Squibb? Is it too late, still worth it? Analysts are split (50% buy, median target $68, i.e. +2%). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Pays a dividend (4.4% yield) — regular income on top of potential upside.
Reasonable valuation (P/E ~15) relative to its sector.

⚠️ Reasons to hesitate

Even the most reliable firm on BMY, Goldman Sachs (100% hit rate, 5 scored calls), only targets $57 (call made on December 2, 2025, maturing on December 2, 2026) (-15%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 10 ratings, 5 are neutral.
Limited upside: the median target is only +2% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on BMY

Median target $68 (+2%) · 10 ratings · Buy consensus

Strong Buy00%

Buy550%

Hold550%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Bristol Myers Squibb now?

We won't decide for you. The facts: 50% of analysts rate it a buy, median target $68 (+2%), and Goldman Sachs (most reliable on BMY, 100%) targets $57. Weigh that against valuation (P/E ~15). This is not personalized advice.

Is it too late to invest in Bristol Myers Squibb?

The stated upside is small: the median target ($68) sits just +2% from the price ($67) (most reliable on BMY: Goldman Sachs, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Bristol Myers Squibb still worth investing in?

It depends on the gap between the price ($67) and its estimated value: analysts target $68 on median (+2%), with 50% buys (most reliable on BMY: Goldman Sachs, 100%). Cross-check with their real reliability on BMY and the cautions above. Information, not advice.

What's the main risk in buying BMY?

Even the most reliable firm on BMY, Goldman Sachs (100% hit rate, 5 scored calls), only targets $57 (call made on December 2, 2025, maturing on December 2, 2026) (-15%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Bristol Myers Squibb profile (consensus, analyst reliability, price target, performance).